Lassen Therapeutics Announces Oral Presentation of Phase I Data of LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting ...

CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid ...

OncoNano announces a presentation of data from its ongoing Phase 2 study of pegsitacianine at the World Molecular Imaging Congress on September 29.

This coincided with the presentation of data related to nimacimab at the American Diabetes Association’s/ADA 85th Scientific Sessions, which was held from June 20 to 23 this year in Chicago ...